Differential proteomic analysis of human genetic prion disease patients in frontal lobe tissues
10.3760/cma.j.issn.1003-9279.2017.03.002
- VernacularTitle: 遗传性朊病毒病额叶脑组织差异蛋白质组学研究
- Author:
Yanjun GUO
1
;
Qi SHI
2
;
Baoyun ZHANG
2
;
Jianle LI
1
;
Luning WANG
3
;
Honghong ZHANG
3
;
Yazhuo HU
3
;
Zhitao HAN
3
;
Weiqin ZHAO
1
;
Dexin WANG
1
;
Xiaoping DONG
2
;
Shuang WU
4
Author Information
1. Department of Neurology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
2. National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
3. Department of Geriatric Neurology, PLA General Hospital, Beijing 100853, China
4. College of Biochemical Engineering Beijing Union University, Beijing Key Laboratory of Biomass Waster Resoure Utilization, Beijing 100023, China
- Publication Type:Journal Article
- Keywords:
Prion disease;
Proteomics;
Fluorescence two-dimensional Differential gel electrophoresis (2D-DIGE);
Biomarker
- From:
Chinese Journal of Experimental and Clinical Virology
2017;31(3):189-194
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To search for biomarkers for human familial prion disease.
Methods:Two-dimensional differential gel electrophoresis (2D-DIGE) proteomic analysis has been performed in frontal lobe tissues of 3 patients suffering from human familial prion disease (PrP) and 3 age-and sex-matched patients suffering from sudden death due to heart failure without neurological disease.
Results:The maps revealed 14 polypeptide chains differentially modulated in the PrP samples, among those, 7 could be identified upon digestion and MALDI-TOF/MS analysis, of which 6 appeared to be up-regulated, 1 being down-regulated.
Conclusions:We highlight Galectin-1(Gal-1), ryanodine receptor 2 (RyR2), ubiquitin, Rab-interacting lysosomes protein-like protein 1 (RILPL-1) profillin 2 (PFN2), in the differential map. These proteins are related to neurogenesis, the clearance of misfolded proteins, stasis of calium channel, myoclonus and so on. These proteins are potential biomarkers or targets for treatment of prion disease.
